S&P Futures
3,925.75+3.25(+0.08%)Dow Futures
31,986.00+70.00(+0.22%)Nasdaq Futures
13,295.25-6.75(-0.05%)
33.83 +0.08 (0.24%)
After hours: 7:59PM EST
Chart Events
Performance Outlook
| Previous Close | 33.91 |
| Open | 33.87 |
| Bid | 33.80 x 1000 |
| Ask | 33.81 x 4000 |
| Day's Range | 33.67 - 34.05 |
| 52 Week Range | 26.45 - 43.08 |
| Volume | 29,848,976 |
| Avg. Volume | 42,057,736 |
| Market Cap | 187.596B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | 19.77 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.56 (4.60%) |
| Ex-Dividend Date | Jan 28, 2021 |
| 1y Target Est | N/A |
Fair Value
Related Research
- Reuters
English survey finds high antibody levels from Pfizer vaccine roll-out
People in England who have received two doses of Pfizer COVID-19 vaccine are generating strong antibody responses as the shot is rolled out, researchers said on Thursday, adding that confidence in vaccines was high. An Imperial College London survey showed 87.9% of people over the age of 80 tested positive for antibodies after two doses of the Pfizer-BioNTech vaccine, rising to 95.5% for those under the age of 60 and 100% in those aged under 30. "Although there is some fall-off in positivity with age, at all ages, we get that very good response to two doses of the vaccine," Paul Elliott, Chair in Epidemiology and Public Health Medicine, Imperial College London, told reporters.
- Barrons.com
How Pfizer Plans to Combat Covid-19 Variants
Pfizer's chief scientist said it was imperative for countries to work together to identify Covid-19 variants taking hold in vaccinated people.
- Reuters
In boost for COVID-19 battle, Pfizer vaccine found 94% effective in real world
The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing COVID-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies. Up until now, most data on the efficacy of COVID-19 vaccines has come under controlled conditions in clinical trials, leaving an element of uncertainty over how results would translate into the real world with its unpredictable variables. The research in Israel - two months into one of the world's fastest rollouts, providing a rich source of data - showed two doses of the Pfizer shot cut symptomatic COVID-19 cases by 94% across all age groups, and severe illnesses by nearly as much.
